Valeo Pharma Inc.
VPHIF · OTC
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.8% | 4.4% | 3.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 27.3% | 19.4% | 15.5% | 4.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -29.2% | -23.6% | -31.8% | -37.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -65% | -55.3% | -50.8% | -70.5% |
| EPS Diluted | -0.083 | -0.079 | -0.08 | -0.098 |
| % Growth | -4.8% | 0.8% | 18.8% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |